Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()

INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a treatment option in the second- or third-line palliative setting in EGFR wild-type (wt) non–small cell lung cancer (NSCLC) patients. However, response rates are low, and only approximately 25% will achieve...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Transl Oncol
Prif Awduron: Winther-Larsen, Anne, Fledelius, Joan, Demuth, Christina, Bylov, Catharina M, Meldgaard, Peter, Sorensen, Boe S
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Neoplasia Press 2016
Pynciau:
Original article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5094375/
https://ncbi.nlm.nih.gov/pubmed/27816687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2016.09.003
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg